OTCMKTS:LOGC LogicBio Therapeutics (LOGC) Stock Price, News & Analysis $8.56 -0.21 (-2.37%) As of 03:55 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock About LogicBio Therapeutics Stock (OTCMKTS:LOGC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LogicBio Therapeutics alerts:Sign Up Key Stats Today's Range$8.45▼$8.8550-Day Range$7.85▼$8.8052-Week Range$6.40▼$9.14Volume149,469 shsAverage Volume146,090 shsMarket Capitalization$391.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. Read More LogicBio Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreLOGC MarketRank™: LogicBio Therapeutics scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for LogicBio Therapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of LogicBio Therapeutics is -7.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LogicBio Therapeutics is -7.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLogicBio Therapeutics has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about LogicBio Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.12% of the float of LogicBio Therapeutics has been sold short.Short Interest Ratio / Days to CoverLogicBio Therapeutics has a short interest ratio ("days to cover") of 3.63, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LogicBio Therapeutics has recently decreased by 0.31%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLogicBio Therapeutics does not currently pay a dividend.Dividend GrowthLogicBio Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for LogicBio Therapeutics this week, compared to 0 articles on an average week.MarketBeat Follows2 people have added LogicBio Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LogicBio Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders42.47% of the stock of LogicBio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.05% of the stock of LogicBio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LogicBio Therapeutics' insider trading history. Receive LOGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LOGC Stock News HeadlinesLogicBio Therapeutics (OTCMKTS:LOGC) vs. Onion Global (NYSE:OG) Head-To-Head ReviewMay 17, 2026 | americanbankingnews.comContextLogic Holdings Inc. Reports First-Quarter 2026 Financial ResultsMay 15, 2026 | globenewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 21 at 1:00 AM | InvestorPlace (Ad)Financial Contrast: LogicBio Therapeutics (OTCMKTS:LOGC) versus MYT Netherlands Parent B.V. (NYSE:MYTE)May 15, 2026 | americanbankingnews.comHead to Head Comparison: Onion Global (NYSE:OG) and LogicBio Therapeutics (OTCMKTS:LOGC)May 13, 2026 | americanbankingnews.comLogicBio Therapeutics (LOGC) Projected to Post Quarterly Earnings on WednesdayMay 11, 2026 | americanbankingnews.comContextLogic Appoints Paul S. Levy to Board of DirectorsApril 1, 2026 | globenewswire.comContextLogic Holdings Inc. Reports Fourth-Quarter and Fiscal Year 2025 Financial ResultsMarch 5, 2026 | globenewswire.comSee More Headlines LOGC Stock Analysis - Frequently Asked Questions How have LOGC shares performed this year? LogicBio Therapeutics' stock was trading at $7.58 at the start of the year. Since then, LOGC shares have increased by 13.5% and is now trading at $8.60. How were LogicBio Therapeutics' earnings last quarter? LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) issued its earnings results on Friday, May, 9th. The company reported ($0.27) EPS for the quarter. Read the conference call transcript. How do I buy shares of LogicBio Therapeutics? Shares of LOGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LogicBio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that LogicBio Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), Compass Pathways (CMPS), Ginkgo Bioworks (DNA), Luminar Technologies (LAZR), Toast (TOST) and Globant (GLOB). Company Calendar Last Earnings5/09/2025Today5/21/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorRetail/Wholesale Industry Catalog & mail - order houses Sub-IndustryN/A Current SymbolOTCMKTS:LOGC CIK1664106 Webwww.logicbio.com Phone(617) 245-0399FaxN/AEmployees62Year Founded2014Profitability EPS (Trailing Twelve Months)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29 million Net MarginsN/A Pretax Margin-156.79% Return on Equity-1.73% Return on Assets-1.22% Debt Debt-to-Equity Ratio0.28 Current Ratio1.67 Quick Ratio31.14 Sales & Book Value Annual Sales$43 million Price / Sales9.09 Cash FlowN/A Price / Cash FlowN/A Book Value$16.24 per share Price / Book0.53Miscellaneous Outstanding Shares45,670,000Free Float26,276,000Market Cap$391.05 million OptionableNo Data Beta2.10 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:LOGC) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LogicBio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LogicBio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
